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Abstract – Remifentanil is a new opioid derivative drug 
characterized by a fast onset and by a short time of action, 
since it is rapidly degraded by esterases in blood and other 
tissues. Its pharmacokinetic and pharmacodynamics 
properties make remifentanil a very interesting molecule in 
the field of anesthesia. However a complete and versatile 
pharmacokinetic description of remifentanil still lacks. In 
this work a three-compartmental model has been developed 
to describe the pharmacokinetics of remifentanil  both in the 
case in which it is administered by intravenous constant-rate 
infusion and by bolus injection. The model curves have been 
compared with experimental data published in scientific 
papers and the model parameters have been optimized to 
describe both ways of administration. The ad hoc model is 
adaptable and potentially useful for predictive purposes. 
 




I.  INTRODUCTION 
 
The topic of the development of new opioid 
anesthetic agents is mainly  to increase potency, and 
reduce the cardiovascular toxicity. For this purposes, 
recently a new kind of opioid derivative drug, 
remifentanil, has been synthetized. Remifentanil is an 
ultra-short acting opioid and it is subjected to metabolism 
by esterases in blood and other tissues. In vivo studies 
demonstrated an extensive metabolism of this drug by 
ester hydrolysis [1]. The primary metabolic pathway 
experienced by remifentanil is the format ion of a 
carboxylic acid metabolite (named GI90291) obtained by 
de-esterification. The chemical structures of remifentanil 
and its primary metabolite are shown in Fig  1. It  has been 
demonstrated on animals [1] that the pharmacodynamics 
of remifentanil is very similar to the other opioid drugs, 
this fact, combined with the reduced effects on the 
cardiovascular system makes the use of remifentanil very 
attractive in anesthesia. Remifentanil is generally 
administrated by the intravenous route. Because of the 
very short half-life of the drug, usually a bolus inject ion is 
administered to raise the blood concentration 
immediately, then a slower intravenous infusion is used to 
maintain the effective plasma concentration. Even if it is 
recommended to infuse remifentanil only during general 
anaesthesia procedures, the single/repeated bolus 
injections could be used in clinical situation in which a 
brief period of intense analgesia is required  and the set -
up of a continuous infusion pump is difficult  (i.e. painful 
diagnostic and therapeutic procedures outside the 
operating theater). For th is reason, it is particularly 
interesting to model what happen in the plasma 
concentration of remifentanil after the bolus injection or 
continuous infusion admin istration. Different kinds of 
models have been proposed, the simplest of which  is the 
compartmental one [2], alternatively, the physiologically 





Fig 1. Chemical structures of remifentanil and its metabolite. 
 
The aim of the present work is to develop and 
validate a new simple model using the compartmental 
modeling approach to evaluate the remifentanil plasma 
concentration in case of bolus injection and continuous 
infusion.  
 
II.  MODELING 
 
In the three-compartmental modeling, three 
compartments describe the fate of a drug once 
administered: the central compartment, which represents 
the plasma; the highly  perfused compartment, which 
represents the organs and tissues highly perfused by the 
blood; and the scarcely perfused compartment, which 
represents the organs and tissues scarcely perfused by 




Fig 2. A schematic of the three-compartmental model. 
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To model the pharmacokinetic of remifentanil, the 
case of intravenous infusion has been studied. Thus, an 
amount of drug has been evaluated as inlet in the central 
compartment. The processes which cause the variation of 
the plasma concentration are: the absorption, the 
distribution, and the excretion of the drug. These 
phenomena have to be taken into account in the modeling. 
I(t) is defined as the function which  describes the drug 
introduction by intravenous infusion (which could be an 
infusion at constant rate of administration or a bolus) in 
the central compartment. The drug concentration in the 
compartments could be evaluated solving the mass 
balance in the compartments, which could be written as: 
 
Central compartment: 

















V    






V    
In which, CP, C2, and C3 are, respectively, the drug 
concentrations of the central, high ly perfused, and 
scarcely perfused compartments . V1, V2, and V3 are, 
respectively, the volumes of the central, h ighly perfused, 
and scarcely perfused compartments. Cl1, Cl2, and Cl3 are, 
respectively, the clearances (rates of drug elimination) of 
the central, h ighly perfused, and scarcely perfused 
compartments. k12 and k21 are the transport coefficients 
between the central and the highly perfused 
compartments; k13 and k31 are the transport coefficients 
between the central and the scarcely perfused 
compartments. Finally, k10 is the kinetic constant of drug 
elimination from the central compartment. The kinetics of 
elimination and transport between the compartments have 
been considered first order kinetics. These equations have 




















The three equations are inter-dependent, thus, they 
have to be solved simultaneously to evaluate the drug 
concentration in all the compartments. 
Once identified the transport phenomena which take 
place in the compartments and defined the differential 
equations able to solve the mass balances in the 
compartments, the value of the parameters has to be 
evaluated. To evaluate the parameters value, the model 
has been used to fit the experimental data taken in 
literature [4, 5], which refer both to intravenous infusion 
and bolus. Defining an error between the e xperimental 

















In which n is the number of experimental data for 
each experiment,  p,iPmPi tCC   is the difference 
between the experimental plas ma concentration  and the 
model pred iction at the t ime ti, p  being the vector of the 
model parameters. Min imizing this function it is possible 
to find the values of the parameters which  better approach 
the experimental data.  
The set of three ODEs constituting the model have 
been solved by a code developed using Matlab, and the 
same software was used to find the value of p  minimizing 




The model simulat ions obtained are shown in Fig 3 
and compared  with the experimental data [5] in the case 
of intravenous constant-rate infusion. Each curve has been 
obtained as average values due to the administration to 
two subjects. During the 20 minutes infusion, a total of 14 
blood samples were taken. After stopping the infusion, 16 
blood samples were taken, up to 240 min after the stop. 
Therefore, each history was described by 30 sample data.   
 
As could be seen from the graphs, the model 
reproduces satisfactorily the experimental data. In 
particular, the plas ma concentration following the 





approximated, however, the concentration of higher doses 




) are not well approximated for 
periods longer than 90 minutes, this is probably due to the 
fact that the supposed elimination kinetic could be still 
optimized.  
 
Furthermore, the same model has been used to 
reproduce the remifentanil plasma concentrations in the 
case of bolus injection and compared with the 
experimental data [4] in  Fig  4. In this case the 
administration has been evaluated as a fast infusion 
(bolus), thus the plasma concentration immediately rise to 
a high value. Each curve has been obtained as the average 
value over six patients (three men and three women). 
Over 360 minutes, 21 blood samples were collected and 
assayed for remifentanil. Once again, the model curves 
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Fig 3. Comparison between the experimental plasma concentration value 
[5] and the model curves in the case of intravenous constant-rate 
infusion with an infusion time of 20 minutes. a1) plasma concentration 

















Fig 4. Comparison between the experimental plasma concentration value 
[4] and the model curves in the case of fast intravenous infusion (bolus).  
b1) plasma concentration after a dose of 2 µg∙kg
-1
;  




TABLE I. Values and dimensions of the three-compartmental model 
parameters. 
Parameter O ptimized value Parameter O ptimized value  
V1 7.88 mL k10 0.172 min
-1
 
V2 23.9 mL k12 0.373 min
-1
 















   
 
The values of the model parameters obtained after the 
optimization routine, are shown in Table 1. The model 
developed has been used to evaluate the plasma 
concentration both in the case of intravenous constant-rate 
infusion and intravenous bolus, which has been 
reproduced simulating a very fast infusion in the central 
compartment. This is a remarkable improvement to the 
compartmental modeling: in fact, once the model 
parameters have been evaluated fo r a certain 
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administration, the model is able to predict the drug 
plasma concentration varying not only the dose, but also 
the infusion rate of the drug. 
 
 
Fig 4 (continue). Comparison between the experimental plasma 
concentration value [4] and the model curves in the case of fast 
intravenous infusion (bolus).  
b3) plasma concentration after a dose of 15 µg∙kg
-1
;  




IV.  CONCLUSIONS 
 
In this work a three-compartmental model has been 
developed to reproduce the evolution of remifentanil 
plasma concentrations after intravenous constant-rate 
infusion and intravenous bolus . The main phenomena of 
absorption, distribution, and metabolis m have been 
identified and the mass balances for the three 
compartments have been written. The model has been 
then used to reproduce plasma concentrations taken from 
literature and the best values of the model parameters 
have been found minimizing the error between model 
curves and experimental data.  
Several studies have been conducted to develop a 
model which is able to reproduce the remifentanil 
pharmacokinetics. The aim of these studies is to compare 
the measured pharmacokinetic features of remifentanil 
after an intravenous infusion to the model predict ion [6]. 
In particu lar, the compartmental analysis has been 
extensively used and compared with the experimental 
data, taken after intravenous infusion [5] or bolus [4]. 
Blood concentration and time data after a computer-
controlled infusion of remifentanil could be analyzed by 
nonlinear regression using the NONMEM program 
(University of Californ ia) [7] which may produce 
predicted and individually predicted values (post hoc 
Bayesian estimates). The initial two-stage analysis 
comparing one-, two-, and three-compartmental models 
found that the two-compartmental model shows the best 
fit to the experimental data. This result was also 
confirmed by a population analysis. A more complex 
analysis of both pharmacokinetics and pharmacodynamics 
of remifentanil has been also approached [8]. The 
pharmacokinetic/pharmacodynamic relat ionship has been 
evaluated using non-linear regression analysis. The 
pharmacokinetics have been described using a one-
compartment intravenous infusion model. Moreover, the 
pharmacodynamics have been fitted using inhib itory 
model. A statistical evaluation of the goodness of the 
models has been carried out following the Akaike 
Information Criterion [9]. According to this analysis, the 
decrease of the SSE using a model with a large number of 
parameters is useful if and only if it overcomes  the 
increase in  the number o f parameters with respect to the 
use of a model with a limited number of parameters. In 
this case, the simple model has shown the best overall 
fitting results. 
Nevertheless, once the value of the parameters has 
been evaluated, our simple model was able to describe the 
remifentanil concentration on blood for different ways of 
administration. This is a remarkable improvement to the 
compartimental modelling: in fact once the model 
parameters have been evaluated for a certain kind of 
administration, the model is able to predict the drug 
plasma concentration varying not only the dose but also 
the infusion rate of the drug. This feature makes the 
model more versatile than the other available in literature 
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